SLC5A2 and cancer: The GLP-1RA/no insulin group (n = 48 983) compared with the insulin/no GLP-1RA group (n = 1 044 475) was younger; included more women and White participants; had a higher prevalence of family history of cancer, obesity or overweight, medical encounters for cancer screening, and prior prescriptions of other antidiabetic agents, including insulins, metformin, dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, sulfonylureas, thiazolidinediones, and α-glucosidase inhibitors.